Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Japan’s JSR Buys U.S. Biologics Maker

by Jean-François Tremblay
March 9, 2015 | A version of this story appeared in Volume 93, Issue 10

Continuing a push into the life sciences field, Japanese chemical maker JSR will join with two partners to buy KBI Biopharma, a U.S.-based contract biopharmaceutical producer. Based in Durham, N.C., KBI offers manufacturing in mammalian-cell-based bioreactors with a capacity of up to 2,000 L. JSR, which will own the majority of KBI, says the acquisition will help it become a recognized player in the biopharmaceutical market. In recent years JSR has invested in the cell-culture and antibody purification businesses.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.